Medivir outlicenses MIV-210 to Daewoong Pharmaceutical Co. Ltd. for clinical development
Medivir AB (Sweden) today announced a license agreement with Daewoong Pharmaceutical Co. Ltd., (South Korea) for its hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210). Under the terms of the agreement, Daewoong Pharmaceutical Co. Ltd. will assume responsibility for clinical development and have marketing rights in South Korea, Japan and China (including Taiwan, Macao and Hong Kong). Medivir is entitled to upfront, milestones and royalties on sales up to double-digital level, and has retained the exclusive marketing rights in the rest of the world. Daewoong